|
Gene: FBXO21 |
Gene summary for FBXO21 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FBXO21 | Gene ID | 23014 |
Gene name | F-box protein 21 | |
Gene Alias | FBX21 | |
Cytomap | 12q24.22 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RBL8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23014 | FBXO21 | LZE4T | Human | Esophagus | ESCC | 5.66e-12 | 2.85e-01 | 0.0811 |
23014 | FBXO21 | LZE7T | Human | Esophagus | ESCC | 5.10e-10 | 5.87e-01 | 0.0667 |
23014 | FBXO21 | LZE8T | Human | Esophagus | ESCC | 1.10e-10 | 4.30e-01 | 0.067 |
23014 | FBXO21 | LZE20T | Human | Esophagus | ESCC | 1.42e-04 | 1.43e-01 | 0.0662 |
23014 | FBXO21 | LZE22D1 | Human | Esophagus | HGIN | 2.78e-03 | 1.87e-01 | 0.0595 |
23014 | FBXO21 | LZE22T | Human | Esophagus | ESCC | 5.80e-07 | 4.04e-01 | 0.068 |
23014 | FBXO21 | LZE24T | Human | Esophagus | ESCC | 1.01e-14 | 5.32e-01 | 0.0596 |
23014 | FBXO21 | LZE21T | Human | Esophagus | ESCC | 1.33e-03 | 2.36e-01 | 0.0655 |
23014 | FBXO21 | P1T-E | Human | Esophagus | ESCC | 9.71e-03 | 4.24e-01 | 0.0875 |
23014 | FBXO21 | P2T-E | Human | Esophagus | ESCC | 8.90e-83 | 1.20e+00 | 0.1177 |
23014 | FBXO21 | P4T-E | Human | Esophagus | ESCC | 3.83e-34 | 9.10e-01 | 0.1323 |
23014 | FBXO21 | P5T-E | Human | Esophagus | ESCC | 3.31e-12 | 3.12e-01 | 0.1327 |
23014 | FBXO21 | P8T-E | Human | Esophagus | ESCC | 7.46e-30 | 5.87e-01 | 0.0889 |
23014 | FBXO21 | P9T-E | Human | Esophagus | ESCC | 2.45e-11 | 2.58e-01 | 0.1131 |
23014 | FBXO21 | P10T-E | Human | Esophagus | ESCC | 1.82e-26 | 5.49e-01 | 0.116 |
23014 | FBXO21 | P11T-E | Human | Esophagus | ESCC | 4.32e-13 | 5.66e-01 | 0.1426 |
23014 | FBXO21 | P12T-E | Human | Esophagus | ESCC | 2.39e-25 | 5.94e-01 | 0.1122 |
23014 | FBXO21 | P15T-E | Human | Esophagus | ESCC | 5.58e-27 | 6.04e-01 | 0.1149 |
23014 | FBXO21 | P16T-E | Human | Esophagus | ESCC | 2.76e-29 | 6.46e-01 | 0.1153 |
23014 | FBXO21 | P17T-E | Human | Esophagus | ESCC | 4.73e-11 | 3.43e-01 | 0.1278 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXO21 | SNV | Missense_Mutation | c.307N>T | p.Arg103Trp | p.R103W | O94952 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
FBXO21 | insertion | Frame_Shift_Ins | novel | c.432_433insT | p.Glu145Ter | p.E145* | O94952 | protein_coding | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FBXO21 | deletion | Frame_Shift_Del | rs772635228 | c.432delT | p.Phe144LeufsTer9 | p.F144Lfs*9 | O94952 | protein_coding | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
FBXO21 | deletion | Frame_Shift_Del | rs772635228 | c.432delT | p.Phe144LeufsTer9 | p.F144Lfs*9 | O94952 | protein_coding | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
FBXO21 | SNV | Missense_Mutation | novel | c.1738C>T | p.Pro580Ser | p.P580S | O94952 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO21 | SNV | Missense_Mutation | novel | c.798N>A | p.Asn266Lys | p.N266K | O94952 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FBXO21 | SNV | Missense_Mutation | c.805N>T | p.Leu269Phe | p.L269F | O94952 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
FBXO21 | SNV | Missense_Mutation | rs772663521 | c.673G>A | p.Val225Met | p.V225M | O94952 | protein_coding | tolerated(0.09) | benign(0.244) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FBXO21 | SNV | Missense_Mutation | novel | c.1441N>T | p.Arg481Cys | p.R481C | O94952 | protein_coding | deleterious(0) | possibly_damaging(0.799) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
FBXO21 | SNV | Missense_Mutation | novel | c.520N>T | p.Arg174Trp | p.R174W | O94952 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |